Samsung Bioepis Presents Results of SB11 (proposed biosimilar ranibizumab) at ARVO 2021

 Samsung Bioepis Presents Results of SB11 (proposed biosimilar ranibizumab) at ARVO 2021

Shots:

  • The company reported the results from a study based on the structural and functional analysis of SB11, a proposed biosimilar referencing Lucentis (ranibizumab)
  • The analytical assessment demonstrated that structural, physicochemical characterization i.e. amino acid sequence, post-translational modifications, higher order structure, and size and charge variants of SB11 were similar to Lucentis
  • The SB11 is also functionally similar to Lucentis based on a set of bioassays and binding assays covering a broad range of VEGF-related functional activities. SB11 is under review by the US FDA and EMA

Click here to­ read full press release/ article | Ref: Globenewswire | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post